MARKETS & MATERIALS
Data & sources →

Nasdaq · dated source prices · weekly rankings in the Weekly 250

THE GLOBAL FINANCIAL WEEKLYNovember 9–15, 2026Vol. 01 · No. 005

DEALS • LISTINGS • PRIVATE MARKETS • OVERSIGHT

Companies & Capital

The week in reporting and analysis. November 9–15, 2026.

M&A + Buy/Sell Signaling

Announced ownership structure

Original analytical illustration; not measured quantities

01H.I.G. affiliate
02Majority stake
03go asia
04Family reinvestment
November 11 agreement; approvals pending, exact percentages and price undisclosed. [1]

Sources: [1] H.I.G. Capital: agreement to acquire majority stake in go asia · 2026-11-11; definitive agreement, subject to approvals

H.I.G. Agrees to Buy Control of go asia

The German food-retail transaction combines outside capital with continuing family ownership; undisclosed terms limit valuation conclusions.

Sources: H.I.G. Capital: agreement to acquire majority stake in go asia

Read the report →
Explore this topic →

Private Market Offerings

What the announced capital is intended to support

Original analytical illustration; not measured quantities

01$21m Series A
02Product development
03Commercial expansion
Company announcement, November 12; no percentage allocation disclosed. [1]

Sources: [1] Nebuly: $21 million Series A announcement · 2026-11-12; issuer announcement, terms incompletely disclosed

Nebuly Raises Capital to Measure AI’s Business Value

A $21 million Series A announcement turns the investment question toward measurable outcomes rather than software usage alone.

Sources: Nebuly: $21 million Series A announcement; SEC: Private Placements, Rule 506(b)

Read the report →
Explore this topic →

IPO's

Expected gross proceeds before fees

USD million; public amount rounded

087.5175175Public IPO50Private placement
November 12 pricing; expected November 16 closing remains prospective. [1]

Sources: [1] Windward Bio: pricing announcement filed under Rule 433 · 2026-11-12; closing expected November 16, after cutoff

Windward Prices Its IPO Alongside a Private Placement

A clinical-stage biotechnology offering illustrates why the public share sale, strategic financing and closing timetable must be read separately.

Sources: Windward Bio: pricing announcement filed under Rule 433; SEC Investor.gov: Updated Investor Bulletin, Investing in an IPO

Read the report →
Explore this topic →

Antitrust & Financial Oversight

The contested transaction

Original analytical illustration; not measured quantities

01Cencora / MWI
02Proposed sale
03Covetrus
04FTC + states challenge
November 13 challenge; no final judgment reported. [1]

Sources: [1] FTC: challenge to Covetrus acquisition of MWI · 2026-11-13; allegations in a newly announced court proceeding

FTC Challenges a Veterinary Distribution Merger

The $3.5 billion Covetrus–MWI transaction enters litigation over the competitive choices available to veterinary practices.

Sources: FTC: challenge to Covetrus acquisition of MWI

Read the report →
Explore this topic →